Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)

NCT03842982 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT03842982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03842982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)
Lead sponsor
Centre Oscar Lambret
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 3, 2019
Completion date
February 1, 2031
Enrollment
362 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, ovarian carcinoma, ovary neoplasms